DarioHealth Posts $5.3M Q3 Revenue as Covenant Breach Looms
DRIO sits 25% above its 52-week low of $1.695 on elevated volume (1.9× avg).
Summary
DarioHealth reported $5.3M of third-quarter revenue, the top line from the 10-Q it filed this morning, beating estimates on higher D2C sales. The filing also showed a $8.8M quarterly loss, narrower than the $10.5M loss a year ago, and $27.8M of cash. The balance sheet carries the real weight here: the company breached its Callodine EBITDA covenant at quarter-end and cured it using $22.8M of proceeds from a July offering. With a $20M at-the-market program and a $100M shelf already in place, dilution remains the central risk for a company this small. Watch whether the $5.3M revenue base and the covenant cure hold through the fourth quarter.
At the time of this announcement, DRIO was trading at $2.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $1.70 to $14.77. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.